| Document |
Document Title |
|
WO/2022/268825A1 |
The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.
|
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/266082A1 |
Disclosed is a method of preparing diroximel fumarate represented by the following structural formula (I) The method comprises reacting ethylene carbonate with succinimide to form a hydroxyethyl succinimide intermediate; and reacting the...
|
|
WO/2022/266363A1 |
Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibit...
|
|
WO/2022/264971A1 |
The present disclosure provides a method for evaluating the quality of sperm. The present disclosure provides a method for evaluating the quality of sperm, said method comprising: a step for obtaining a mixed solution by mixing a sperm...
|
|
WO/2022/262657A1 |
The present invention relates to an N-substituted phenylsulfonamide compound and a use thereof. Specifically, the present invention provides a compound represented by formula I, or an optical isomer thereof, or a racemate thereof, or a p...
|
|
WO/2022/261473A1 |
The application relates to compounds of Formula (I) and (III), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory sy...
|
|
WO/2022/259266A1 |
The present invention relates to functionalized Maleimides and Isomaleimides of general Formula (I) and a process for the preparation thereof, involving [3+2] annulation of α, β-5 unsaturated aldehydes with carbamoyl alkylates via an e...
|
|
WO/2022/256482A1 |
Provided are methods for making crystalline forms of (S)-(-)-amisulpride and (R)-(+)-amisulpride. Also provided are pharmaceutical compositions comprising the crystalline forms of (S)-(-)-amisulpride and (R)-(+)-amisulpride and methods o...
|
|
WO/2022/256267A1 |
Provided are methods of treating or preventing Raynaud's, comprising prescribing and/or administering to an individual in need thereof 3-methoxy-N-[3-(2-methylpyrazol-3-yl)-4-(2-morpholin-4-yleth
oxy)phenyl]benzamide (Compound 1), or a p...
|
|
WO/2022/256434A1 |
Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and metho...
|
|
WO/2022/254027A1 |
The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, ...
|
|
WO/2022/247755A1 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol andpolymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucl...
|
|
WO/2022/251615A1 |
Disclosed are bis-amide inhibitors of SARS-CoV-2 (CO VID), and methods of using them to treat a severe acute respiratory syndrome.
|
|
WO/2022/251280A1 |
Disclosed herein are compounds selective for JAK1, pharmaceutical compositions comprising said compounds, and methods of using said compounds.
|
|
WO/2022/241513A1 |
The present application relates to metal-organic framework (MOF) encapsulation of lipid-nucleic acid formulations. The present application discloses methods for stabilizing lipid-nucleic acid formulations and provides MOF encapsulated li...
|
|
WO/2022/242278A1 |
A method for synthesizing an intermediate of upadacitinib, comprising: (1) compound formula 1 undergoes an epoxidation reaction, an addition reaction, and a protection reaction to obtain compound formula 4; compound formula 4 reacts with...
|
|
WO/2022/243238A1 |
The invention relates to a system (10) for cleaning recovered NMP from a lithium-ion battery production, comprising a first column (16) for separating low-boiling impurities, said first column having a feed (16a) for the recovered NMP in...
|
|
WO/2022/243097A1 |
A process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is re-acted with a compound having at least one nitrogen bearing a substitutable hydrogen residue in a liquid phase in the presence of at least one phosph...
|
|
WO/2022/239987A1 |
The present invention relates to a compound comprising pyrrolidine as a linker, and a pharmaceutically acceptable salt thereof; and to a composition comprising the compound as an active ingredient, for preventing or treating skin conditi...
|
|
WO/2022/237682A1 |
The present invention relates to a salt form of a pyrrolotriazine compound, a crystal form thereof, a preparation method therefor, and an application thereof, and in particular to an application in preparation of MNK1/2 inhibitor drugs a...
|
|
WO/2022/240886A1 |
Forms of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-h
ydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile,
designated herein as Compound I, were prepared and characterized in the solid state. Also provided are pr...
|
|
WO/2022/234595A1 |
The present provides a synergistic insecticidal composition comprising Chlorantraniliprole, Spirotetramat and at least one insecticidal compound selected from Buprofezin, Bifenthrin, Propargite or Pyriproxyfen, process of preparation of ...
|
|
WO/2022/234447A1 |
The invention relates to compounds of general formula (I), having inhibitory activity against the NLRP3 inflammasome. Said compounds are useful in the prevention and/or treatment of diseases and/or disorders mediated by the NLRP3 inflamm...
|
|
WO/2022/229820A1 |
The present invention provides a method suitable for industrial production of a compound of formula (V): (V) comprising a step of subjecting a compound (IV) to an asymmetric reductive amination reaction in the presence of a metal complex...
|
|
WO/2022/228215A1 |
A preparation method for a pyrrole amide compound, as shown in formula (II). The preparation method comprises: reacting a compound of formula (III) with a compound of formula (IV) in the presence of a palladium catalyst and a ligand, whe...
|
|
WO/2022/232088A1 |
Provided herein are compounds of Formula (I'), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), or Formula (VIII) and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tau...
|
|
WO/2022/223295A1 |
The invention relates to asymmetrical methylene bisimides having the formula (I), a method for their preparation and their use for the preparation of resins.
|
|
WO/2022/223599A1 |
The present invention relates to a new class of dielectric polymer material, which is particularly suitable for the manufacturing of electronic devices. The dielectric polymer material is formed by reacting bismaleimide compounds and sho...
|
|
WO/2022/218705A1 |
A process for the continuous production of amines, the process comprising reacting a primary or secondary alcohol with ammonia in the presence of hydrogen and a heterogeneous hydrogenation catalyst in the gas phase using a recycle gas mo...
|
|
WO/2022/219246A1 |
The present invention relates to a compound of formula (I) wherein A, Z, L, R1, R2, R3, R4, R5 and R33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors o...
|
|
WO/2022/213200A1 |
The present invention relates to a process preparing and therapeutic use of endocannabinoid-targeting prodrugs in a delivery system. In particular, the present invention relates to prodrugs of the endocannabinoid system- targeting molecu...
|
|
WO/2022/213195A1 |
There is provided compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are melatonin MT2 agonists, as well as pharmaceutical compositions comprising such compounds. The invention also provides the use of the comp...
|
|
WO/2022/212809A1 |
Processes are provided herein for the preparation of a bicyclic ketone compound of formula (I), or a stereoisomer thereof: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and n are as defined herein; and compounds prepa...
|
|
WO/2022/212707A1 |
The present invention relates to antiviral agents according to Formula (I) and their use in the treatment of viral infection.
|
|
WO/2022/206350A1 |
Provided herein are inhibitors of methionine aminopeptidase 2 (MetAP-2) and pharmaceutical compositions thereof, and their use and methods of treatment, reduction or prevention of certain diseases or conditions associated with MetAP-2 (e...
|
|
WO/2022/206870A1 |
Provided is a preparation and purification process of MMAE. The process has mild synthesis and purification conditions, can effectively prevent the change of product chirality caused by excessively high temperature, greatly reduces gener...
|
|
WO/2022/207935A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for mod...
|
|
WO/2022/206879A1 |
Provided are crystal forms relating to sulfamoyl pyrrole amide compounds and preparation methods therefor. Specifically, two crystal forms A and B of compounds of formula (I) and preparation methods and uses therefor are provided. The pr...
|
|
WO/2022/204907A1 |
Provided is a method for preparing a cocrystal of L-pyroglutamic acid and a glucopyranosyl derivative, which can be used as a sodium-dependent glucose transporter (SGLT) inhibitor. The method is stable and controllable, so the target coc...
|
|
WO/2022/206666A1 |
Provided are a crystalline form of a pyrrole amide compound, a preparation method therefor and a use thereof, and also provided is a pharmaceutical composition comprising the crystalline form. In particular, the crystalline form or the p...
|
|
WO/2022/199124A1 |
Disclosed in the present invention is a method for synthesizing a lactam compound, comprising: (1) under gas protection, dissolving N-F benzenesulfonamide and acyl chloride in an organic solvent, uniformly stirring, and performing a reac...
|
|
WO/2022/200444A1 |
The present invention relates to a new process for preparing 5-{5-chloro-2-[(3S)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1H)-carbo
nyl]phenyl}-1,2-dimethyl- 1H-pyrrole-3 -carboxylic acid derivatives and its application for ...
|
|
WO/2022/204080A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2022/200208A1 |
Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidally active substances The present invention relates to substituted pyrrolidin-2-ones of the general formula (I) or salts thereof, (I) where the radicals in the genera...
|
|
WO/2022/063899A9 |
The present invention relates to (/?)-4-[5-(4-chlorophenyl)-1-[2-(trifluoromethyl)- phenyl]pyrrol-2-yl]-N-[2-(dimethylamino)-ethyl]benzamide (+)-L-tartrate salt, methods for its preparation, pharmaceutical compositions containing it and ...
|
|
WO/2022/197182A1 |
The present invention pertains to improved methods for preparing cyclooctenes and conjugates thereof. In particular, methods for regioselective modification and/or enantiomerically enriching compounds are disclosed. In addition, compound...
|
|
WO/2022/196734A1 |
Provided is a fluorine-containing compound represented by formula (1) or formula (2) (R1, R2, and R3 in formula (1) and R4 and R5 in formula (2) are a C1-10 alkyl group that is unsubstituted or substituted by a fluorine atom-free substit...
|
|
WO/2022/197944A1 |
Pyrrole compounds are produced by contacting a furan compound, a solid acid catalyst, and water to form a reaction mixture containing a γ-dicarbonyl compound, and then contacting the γ-dicarbonyl compound with ammonia or an ammonium sa...
|
|
WO/2022/189810A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
